JP2002506446A - ランゲルハンス島組織の移植のためのｃｄ１５４遮断治療 - Google Patents

ランゲルハンス島組織の移植のためのｃｄ１５４遮断治療

Info

Publication number
JP2002506446A
JP2002506446A JP50490799A JP50490799A JP2002506446A JP 2002506446 A JP2002506446 A JP 2002506446A JP 50490799 A JP50490799 A JP 50490799A JP 50490799 A JP50490799 A JP 50490799A JP 2002506446 A JP2002506446 A JP 2002506446A
Authority
JP
Japan
Prior art keywords
tissue
insulin
transplant
recipient
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP50490799A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002506446A5 (https=
Inventor
エス． ケンヨン，ノルマ
リコルディ，カミーロ
ダブリュー． トーマス，デイビッド
バークリー，リンダ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Miami
Original Assignee
University of Miami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Miami filed Critical University of Miami
Publication of JP2002506446A publication Critical patent/JP2002506446A/ja
Publication of JP2002506446A5 publication Critical patent/JP2002506446A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Steroid Compounds (AREA)
  • External Artificial Organs (AREA)
JP50490799A 1997-06-20 1998-06-19 ランゲルハンス島組織の移植のためのｃｄ１５４遮断治療 Ceased JP2002506446A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US5026797P 1997-06-20 1997-06-20
US60/050,267 1997-06-20
US7726598P 1998-03-09 1998-03-09
US60/077,265 1998-03-09
PCT/US1998/012892 WO1998058669A2 (en) 1997-06-20 1998-06-19 Cd154 blockade therapy for pancreatic islet tissue transplantation

Publications (2)

Publication Number Publication Date
JP2002506446A true JP2002506446A (ja) 2002-02-26
JP2002506446A5 JP2002506446A5 (https=) 2005-12-22

Family

ID=26728084

Family Applications (1)

Application Number Title Priority Date Filing Date
JP50490799A Ceased JP2002506446A (ja) 1997-06-20 1998-06-19 ランゲルハンス島組織の移植のためのｃｄ１５４遮断治療

Country Status (21)

Country Link
US (2) US20030072754A1 (https=)
EP (1) EP1051191B1 (https=)
JP (1) JP2002506446A (https=)
KR (1) KR100634847B1 (https=)
CN (2) CN1195546C (https=)
AT (1) ATE339966T1 (https=)
AU (1) AU730763B2 (https=)
BG (1) BG64976B1 (https=)
BR (1) BR9810620A (https=)
CA (1) CA2294154A1 (https=)
DE (1) DE69835965T2 (https=)
EA (1) EA002550B1 (https=)
EE (1) EE9900588A (https=)
HU (1) HUP0003160A3 (https=)
IL (1) IL133303A0 (https=)
IS (1) IS5273A (https=)
NO (1) NO996275L (https=)
NZ (1) NZ502052A (https=)
SK (1) SK180299A3 (https=)
TR (1) TR199903142T2 (https=)
WO (1) WO1998058669A2 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999045958A1 (en) * 1998-03-09 1999-09-16 Biogen, Inc. Cd154 blockade therapy for modulation of immune responses to implanted devices
WO2001079555A2 (en) 2000-04-14 2001-10-25 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
CA2410786A1 (en) * 2000-06-02 2001-12-13 Regents Of The University Of Minnesota Immunotherapeutic method to prevent islet cell rejection
WO2001095928A2 (en) * 2000-06-09 2001-12-20 Bristol-Myers Squibb Company Methods for regulating a cell-mediated immune response by blocking lymphocytic signals and by blocking lfa-1 mediated adhesion
EP1639014B1 (en) * 2003-06-13 2010-09-22 Biogen Idec MA Inc. Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof
EA014226B1 (ru) 2004-07-26 2010-10-29 Байоджен Айдек Ма Инк. Антитела к cd154, их фрагменты и способы применения антител и фрагментов
WO2006054305A2 (en) * 2004-11-22 2006-05-26 Ramot At Tel Aviv University Ltd. Populations of expanded and re-differentiated adult islet beta cells capable of producing insulin and methods of generating same
WO2007047539A2 (en) * 2005-10-14 2007-04-26 Medtronic, Inc. Localized delivery to the lymphatic system
US8636995B2 (en) 2006-08-31 2014-01-28 Cardiac Pacemakers, Inc. Methods and devices to regulate stem cell homing
US8372399B2 (en) 2006-08-31 2013-02-12 Cardiac Pacemakers, Inc. Bispecific antibodies and agents to enhance stem cell homing
US8911739B2 (en) 2009-02-10 2014-12-16 Trustees Of Columbia University In The City Of New York Methods of preventing rejection of transplanted tissue by administering anti-CD40L antibody and dendritic cells loaded with Hsp60sp peptide
WO2011146395A2 (en) 2010-05-17 2011-11-24 The Board Of Trustees Of The Leland Stanford Junior University Prevention of immunological rejection of transplanted stem cells by leukocyte costimulatory molecule blockade
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US10147463B2 (en) 2014-12-10 2018-12-04 Nxp Usa, Inc. Video processing unit and method of buffering a source video stream
US9512229B2 (en) * 2015-03-03 2016-12-06 Kymab Limited Synergistic combinations of OX40L antibodies for the treatment of GVHD
KR101810778B1 (ko) * 2015-06-23 2017-12-20 서울대학교산학협력단 Cd154 결합 폴리펩타이드 및 그 용도
US10986309B2 (en) 2015-06-30 2021-04-20 Nxp Usa, Inc. Video buffering and frame rate doubling device and method
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5227298A (en) * 1990-08-17 1993-07-13 The Trustees Of Columbia University In The City Of New York Method for microencapuslation of cells or tissue
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US5683693A (en) * 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
IL125928A (en) * 1996-03-20 2002-11-10 Bristol Myers Squibb Co The use of soluble ligands that react with CTLA4, B7, CD40, gp39 and / or CD28 for the preparation of pharmaceutical preparations

Also Published As

Publication number Publication date
HK1033548A1 (en) 2001-09-07
CN1261286A (zh) 2000-07-26
EP1051191B1 (en) 2006-09-20
IL133303A0 (en) 2001-04-30
DE69835965D1 (de) 2006-11-02
BR9810620A (pt) 2000-10-03
EE9900588A (et) 2000-08-15
AU730763B2 (en) 2001-03-15
NZ502052A (en) 2001-01-26
KR20010013965A (ko) 2001-02-26
DE69835965T2 (de) 2007-06-14
HUP0003160A2 (hu) 2001-01-29
CA2294154A1 (en) 1998-12-30
CN1195546C (zh) 2005-04-06
HUP0003160A3 (en) 2002-09-30
EA200000058A1 (ru) 2000-08-28
BG64976B1 (bg) 2006-11-30
BG104091A (en) 2000-10-31
US20070292440A1 (en) 2007-12-20
TR199903142T2 (xx) 2000-09-21
ATE339966T1 (de) 2006-10-15
NO996275L (no) 2000-02-21
KR100634847B1 (ko) 2006-10-17
IS5273A (is) 1999-11-26
AU7983098A (en) 1999-01-04
NO996275D0 (no) 1999-12-17
EP1051191A2 (en) 2000-11-15
WO1998058669A2 (en) 1998-12-30
SK180299A3 (en) 2000-06-12
CN1651919A (zh) 2005-08-10
US20030072754A1 (en) 2003-04-17
EA002550B1 (ru) 2002-06-27
WO1998058669A3 (en) 1999-04-29

Similar Documents

Publication Publication Date Title
JP2002506446A (ja) ランゲルハンス島組織の移植のためのｃｄ１５４遮断治療
AU735592B2 (en) Use of a CD40:CD154 binding interruptor to prevent counter adaptive immune responses, particularly graft rejection
JP2001501607A (ja) 免疫調節のためのｃｄ４５ｒ白血球抗原に対する抗体の利用
US20030170239A1 (en) Immunotherapeutic method to prevent islet cell rejection
EP1754490A2 (en) CD 154 blockage therapy for pancreatic islet tissue transplantation in primates
CZ461699A3 (cs) Použití činidla rušícího vazbu CD40:CD154 pro přípravu léku k zabránění odhojení štěpu tkáně tvořící inzulín
MXPA99011740A (en) Cd154 blockade therapy for pancreatic islet tissue transplantation
HK1033548B (en) Cd154 blockade therapy for pancreatic islet tissue transplantation in primates
PL191122B1 (pl) Zastosowania przerywacza wiązania CD40:CD154
CN1736483A (zh) 应用cd40：cd154结合阻断物预防反适应性免疫应答,特别是移植物排斥反应
WO1999045958A1 (en) Cd154 blockade therapy for modulation of immune responses to implanted devices
CZ403599A3 (cs) Použití činidla rušícího vazbu CD40:CD154 pro výrobu léku k inhibici odhojení tkáňového štěpu a přípravek obsahující činidlo rušící vazbu CD40:CD154
MXPA99010571A (en) Use of a cd40:cd154 binding interruptor to prevent counter adaptive immune responses, particularly graft rejection

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050616

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050616

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080819

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081118

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081218

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090202

A313 Final decision of rejection without a dissenting response from the applicant

Free format text: JAPANESE INTERMEDIATE CODE: A313

Effective date: 20090401

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090526